{"entity":{"id":"martin-van-den-bent","kind":"person","name":"Martin J. van den Bent","aka":[],"tldr":"Led the EORTC glioma trials that established chemotherapy for anaplastic gliomas and the value of 1p/19q and IDH status.","summary":"Martin van den Bent led EORTC 26951, which showed adjuvant PCV chemotherapy doubles survival in 1p/19q-codeleted anaplastic oligodendroglioma, and the CATNON trial establishing adjuvant temozolomide in non-codeleted anaplastic glioma. He chaired the EORTC Brain Tumour Group and led the EANO glioma guidelines. His work built the molecular framework for glioma classification and treatment.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=van%20den%20Bent%20MJ%5BAuthor%5D%20glioma"}],"tags":["glioma","eortc","chemotherapy"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["erasmus-mc"],"pathways":[],"terms":[],"trials":["eortc-26981"],"people":[],"bottlenecks":[],"keyPapers":["paper-stupp-temozolomide-nejm-2005"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Neuro-Oncology, Erasmus MC Cancer Institute","institutionId":"erasmus-mc","specialisms":["Glioma","Anaplastic glioma","Chemoradiotherapy","EORTC trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=van%20den%20Bent%20MJ%5BAuthor%5D%20glioma"}],"papers":[{"title":"Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma","journal":"Lancet","year":2017,"doi":"10.1016/S0140-6736(17)31442-3"},{"title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951","journal":"JCO","year":2013,"doi":"10.1200/JCO.2012.43.2229"},{"title":"Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma","journal":"New England Journal of Medicine","year":2005,"url":"https://doi.org/10.1056/NEJMoa043330","doi":"10.1056/NEJMoa043330"}],"orcid":"0000-0001-5710-5127"},"route":"/people/martin-van-den-bent/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"institution":[{"id":"erasmus-mc","kind":"institution","name":"Erasmus MC Cancer Institute","route":"/institutions/erasmus-mc/"}],"trial":[{"id":"eortc-26981","kind":"trial","name":"EORTC 26981 / NCIC CE.3 (Stupp trial)","route":"/trials/eortc-26981/"}],"paper":[{"id":"paper-stupp-temozolomide-nejm-2005","kind":"paper","name":"Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma","route":"/key-papers/paper-stupp-temozolomide-nejm-2005/"}]}}